Golf, To this point, I haven't seen any evidence that the plan is to sell this company. It is quite possible. It's also possible that Amarin might use Vascepa to grow the company into something more than what it currently is. The product is unique. The loss of patent protection doesn't immediately cause a loss of the market. We are actually currently seeing a slight growth in US market share. I am going to reserve my opinion until we have more information. Good luck to us investors. Sleven,
Why are so many expecting this Brave study to cause the stock price to skyrocket? What if it is a bust? Also, good news usually does not cause this stock to rise I think Brave is a hail mary at best and a BO is what should be the boards only goal right now.
News 
Market Data 
Discover 
AI
